ZLAB Zai Lab Corp: Koefisien utang jangka dawa marang modal

The visualized price action of Zai Lab Limited (ZLAB) helps assess the monetization of Western cancer and autoimmune pathology drugs in China. The current figure stands at 0.02. The business is based on expansion into the PRC through the introduction of global bestsellers and the growth of its own R&D. Meanwhile, capital stability is coupled with stringent requirements for intellectual property protection and compliance.

This ratio compares liabilities with a maturity of more than one year to net assets, determining the degree of capital dependence on external borrowing and overall financial stability. By analyzing the long-term debt-to-net assets ratio, an investor assesses bankruptcy risk against expansion rates, which is critical for Zai Lab Limited (ZLAB) when scaling its portfolio of licensed drugs and maintaining high cash flow profitability.